280 related articles for article (PubMed ID: 9071080)
21. Comparison of a gonadotropin releasing-hormone antagonist plus testosterone (T) versus T alone as potential male contraceptive regimens.
Bagatell CJ; Matsumoto AM; Christensen RB; Rivier JE; Bremner WJ
J Clin Endocrinol Metab; 1993 Aug; 77(2):427-32. PubMed ID: 8345047
[TBL] [Abstract][Full Text] [Related]
22. Testosterone enanthate at a dose of 200 mg/week decreases HDL-cholesterol levels in healthy men.
Meriggiola MC; Marcovina S; Paulsen CA; Bremner WJ
Int J Androl; 1995 Oct; 18(5):237-42. PubMed ID: 8567093
[TBL] [Abstract][Full Text] [Related]
23. Predictors for partial suppression of spermatogenesis of hormonal male contraception.
Li JW; Gu YQ
Asian J Androl; 2008 Sep; 10(5):723-30. PubMed ID: 18645675
[TBL] [Abstract][Full Text] [Related]
24. [Male contraception in 1987].
Silvestre L; Varin C; Bouchard P
Rev Prat; 1987 Sep; 37(38):2302-11. PubMed ID: 3310192
[TBL] [Abstract][Full Text] [Related]
25. Effects of testosterone enanthate in normal men: experience from a multicenter contraceptive efficacy study. World Health Organization Task Force on Methods for the Regulation of Male Fertility.
Wu FC; Farley TM; Peregoudov A; Waites GM
Fertil Steril; 1996 Mar; 65(3):626-36. PubMed ID: 8774299
[TBL] [Abstract][Full Text] [Related]
26. Rates of suppression and recovery of human sperm output in testosterone-based hormonal contraceptive regimens.
Ly LP; Liu PY; Handelsman DJ
Hum Reprod; 2005 Jun; 20(6):1733-40. PubMed ID: 15860500
[TBL] [Abstract][Full Text] [Related]
27. Testosterone/progestin regimens: a realistic option for male contraception?
Amory JK
Curr Opin Investig Drugs; 2004 Oct; 5(10):1025-30. PubMed ID: 15535423
[TBL] [Abstract][Full Text] [Related]
28. Low dose of cyproterone acetate and testosterone enanthate for contraception in men.
Meriggiola MC; Bremner WJ; Costantino A; Di Cintio G; Flamigni C
Hum Reprod; 1998 May; 13(5):1225-9. PubMed ID: 9647551
[TBL] [Abstract][Full Text] [Related]
29. Drug insight: Recent advances in male hormonal contraception.
Amory JK; Page ST; Bremner WJ
Nat Clin Pract Endocrinol Metab; 2006 Jan; 2(1):32-41. PubMed ID: 16932251
[TBL] [Abstract][Full Text] [Related]
30. Hormonal male contraception: progress and prospects for the 21st century.
Handelsman DJ
Aust N Z J Med; 1995 Dec; 25(6):808-16. PubMed ID: 8770357
[TBL] [Abstract][Full Text] [Related]
31. Suppression of spermatogenesis in man induced by Nal-Glu gonadotropin releasing hormone antagonist and testosterone enanthate (TE) is maintained by TE alone.
Swerdloff RS; Bagatell CJ; Wang C; Anawalt BD; Berman N; Steiner B; Bremner WJ
J Clin Endocrinol Metab; 1998 Oct; 83(10):3527-33. PubMed ID: 9768659
[TBL] [Abstract][Full Text] [Related]
32. Multicenter contraceptive efficacy trial of injectable testosterone undecanoate in Chinese men.
Gu Y; Liang X; Wu W; Liu M; Song S; Cheng L; Bo L; Xiong C; Wang X; Liu X; Peng L; Yao K
J Clin Endocrinol Metab; 2009 Jun; 94(6):1910-5. PubMed ID: 19293262
[TBL] [Abstract][Full Text] [Related]
33. Oral progestogen combined with testosterone as a potential male contraceptive: additive effects between desogestrel and testosterone enanthate in suppression of spermatogenesis, pituitary-testicular axis, and lipid metabolism.
Wu FC; Balasubramanian R; Mulders TM; Coelingh-Bennink HJ
J Clin Endocrinol Metab; 1999 Jan; 84(1):112-22. PubMed ID: 9920070
[TBL] [Abstract][Full Text] [Related]
34. Combined administration of a gonadotropin-releasing hormone antagonist and testosterone in men induces reversible azoospermia without loss of libido.
Pavlou SN; Brewer K; Farley MG; Lindner J; Bastias MC; Rogers BJ; Swift LL; Rivier JE; Vale WW; Conn PM
J Clin Endocrinol Metab; 1991 Dec; 73(6):1360-9. PubMed ID: 1955518
[TBL] [Abstract][Full Text] [Related]
35. A multicenter contraceptive efficacy study of injectable testosterone undecanoate in healthy Chinese men.
Gu YQ; Wang XH; Xu D; Peng L; Cheng LF; Huang MK; Huang ZJ; Zhang GY
J Clin Endocrinol Metab; 2003 Feb; 88(2):562-8. PubMed ID: 12574181
[TBL] [Abstract][Full Text] [Related]
36. Contraceptive efficacy of testosterone-induced azoospermia in normal men. World Health Organization Task Force on methods for the regulation of male fertility.
Lancet; 1990 Oct; 336(8721):955-9. PubMed ID: 1977002
[TBL] [Abstract][Full Text] [Related]
37. Daily testosterone and gonadotropin levels are similar in azoospermic and nonazoospermic normal men administered weekly testosterone: implications for male contraceptive development.
Amory JK; Anawalt BD; Bremner WJ; Matsumoto AM
J Androl; 2001; 22(6):1053-60. PubMed ID: 11700852
[TBL] [Abstract][Full Text] [Related]
38. Depo Provera. Position paper on clinical use, effectiveness and side effects.
Bigrigg A; Evans M; Gbolade B; Newton J; Pollard L; Szarewski A; Thomas C; Walling M
Br J Fam Plann; 1999 Jul; 25(2):69-76. PubMed ID: 10454658
[TBL] [Abstract][Full Text] [Related]
39. Developments in the control of testicular function.
Swerdloff RS; Wang C; Bhasin S
Baillieres Clin Endocrinol Metab; 1992 Apr; 6(2):451-83. PubMed ID: 1377467
[TBL] [Abstract][Full Text] [Related]
40. Intramuscular testosterone undecanoate and norethisterone enanthate in a clinical trial for male contraception.
Kamischke A; Venherm S; Plöger D; von Eckardstein S; Nieschlag E
J Clin Endocrinol Metab; 2001 Jan; 86(1):303-9. PubMed ID: 11232016
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
